Azenta, Inc.

NasdaqGS:AZTA Voorraadrapport

Marktkapitalisatie: US$930.2m

Azenta Toekomstige groei

Future criteriumcontroles 3/6

Azenta zal naar verwachting groeien in winst en omzet met respectievelijk 95.1% en 5% per jaar. De winst per aandeel zal naar verwachting groeien met 90.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 0.9% zijn.

Belangrijke informatie

95.1%

Groei van de winst

90.15%

Groei van de winst per aandeel

Life Sciences winstgroei17.6%
Inkomstengroei5.0%
Toekomstig rendement op eigen vermogen0.85%
Dekking van analisten

Good

Laatst bijgewerkt08 May 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • May 01

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.
Narratiefupdate • Apr 15

AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery

Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.
Narratiefupdate • Apr 01

AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery

Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.
Seeking Alpha • Mar 24

Azenta: Life Science Player Fails To Come To Life

Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking Alpha
Narratiefupdate • Mar 18

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.
Narratiefupdate • Mar 03

AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery

Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
Nieuw narratief • Feb 25

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Feb 17

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
Nieuw narratief • Feb 08

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Feb 03

AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential

Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.
Narratiefupdate • Jan 20

AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward

Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.
Narratiefupdate • Jan 05

AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential

Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.
Narratiefupdate • Dec 14

AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion

Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.
Narratiefupdate • Nov 29

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.
Analyseartikel • Nov 28

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...
Narratiefupdate • Nov 14

AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity

Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.
Narratiefupdate • Oct 30

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.
Analyseartikel • Sep 12

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...
Analyseartikel • Aug 07

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...
Analyseartikel • Jul 24

Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...
User avatar
Nieuw narratief • May 28

Pharma And Biotech Outsourcing Will Shape Future Market Dynamics

Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.
Seeking Alpha • Apr 17

Azenta: Life Science Business Failing To Come To Life

Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking Alpha
Analyseartikel • Apr 05

Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...
Analyseartikel • Mar 28

Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...
Seeking Alpha • Jan 27

Azenta: Taking A Pass

Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Jan 10

At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?

Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...
Analyseartikel • Dec 20

A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...
Analyseartikel • Nov 17

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...
Analyseartikel • Nov 14

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...
Seeking Alpha • Sep 11

Azenta: Life Science Play Is Not Coming To Life

Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking Alpha
Analyseartikel • Jul 19

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...

Winst- en omzetgroeiprognoses

NasdaqGS:AZTA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
9/30/20286752150904
9/30/20276301741806
9/30/2026600-15940736
3/31/2026596-1113062N/A
12/31/2025595263163N/A
9/30/2025594243872N/A
6/30/2025586-275288N/A
3/31/2025586-283972N/A
12/31/2024579-243266N/A
9/30/2024573-241250N/A
6/30/2024595-212462N/A
3/31/2024616-233169N/A
12/31/2023628-91048N/A
9/30/2023551-8-346N/A
6/30/2023630-21-56-13N/A
3/31/2023597-26-500-449N/A
12/31/2022594-25-581-509N/A
9/30/2022555-11-543-466N/A
6/30/2022555-28-530-449N/A
3/31/2022551-23-5916N/A
12/31/2021535-2966122N/A
9/30/2021514-2997150N/A
6/30/2021114-69130175N/A
3/31/2021205-53112156N/A
12/31/2020296-371056N/A
9/30/2020389-26-238N/A
6/30/202085041-1919N/A
3/31/202083428-729N/A
12/31/201981216N/A110N/A
9/30/2019334-61N/A91N/A
6/30/20197413N/A89N/A
3/31/20197107N/A73N/A
12/31/201866872N/A77N/A
9/30/201863268N/A74N/A
6/30/201848835N/A78N/A
3/31/201849847N/A76N/A
12/31/2017510-2N/A81N/A
9/30/201752711N/A96N/A
6/30/201766956N/A85N/A
3/31/201763447N/A82N/A
12/31/2016600-51N/A71N/A
9/30/2016434-85N/A40N/A
6/30/2016549-73N/A38N/A
3/31/2016546-74N/A39N/A
12/31/201555012N/A28N/A
9/30/201555314N/A44N/A
6/30/20155298N/A35N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat AZTA de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.5% ).

Winst versus markt: Er wordt verwacht dat AZTA de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat AZTA binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van AZTA ( 5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van AZTA ( 5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen AZTA zal naar verwachting over 3 jaar laag zijn ( 0.9 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/26 15:19
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/09/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Azenta, Inc. wordt gevolgd door 15 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Christopher MuseBarclays
Brett HodessBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)